Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a collective surge, with notable increases in various companies' stock prices [1] - Xinwei Medical-B saw a rise of over 12%, while Brain Dynamics and Nanjing Panda Electronics both increased by over 7% [1] - Brainhole Technology rose by over 5%, and Micron Brain Science experienced an increase of over 3% [1]

Core Viewpoint - The brain-machine interface sector is experiencing a surge in stock prices following the release of a new regulatory framework by the National Medical Products Administration (NMPA) in China, which includes a list of prioritized high-end medical devices for approval [1] Group 1: Stock Performance - Heartway Medical-B (06609) saw a price increase of 12.22%, reaching 54 HKD [1] - Brain Dynamics-B (06681) rose by 7.78%, trading at 6.79 HKD [1] - Nanjing Panda Electronics (00553) increased by 7.14%, with a price of 4.65 HKD [1] Group 2: Regulatory Developments - On December 26, the NMPA published the "Priority Approval List for High-End Medical Devices (2025 Edition)," which includes eight products, such as implantable brain-machine interface devices [1] - The list outlines the technical parameters and expected uses of the products [1] - The NMPA is actively promoting faster and better market entry for brain-machine interface devices through a dedicated working meeting [1] Group 3: Market Outlook - Guotai Junan Securities notes that recent policies have shown strong support for innovation in medical devices [1] - The brain-machine interface sector has diverse application scenarios and rich product and research pathways, indicating significant future potential [1] - With the support of product registration and medical insurance policy initiatives, commercialization is expected to accelerate [1]

Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a collective surge, with notable increases in stock prices for several companies [1] - Heartway Medical-B saw a rise of over 12%, while Brain Dynamics-B and Nanjing Panda Electronics both increased by over 7% [1] - The Fifth Frontier Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo commenced on December 28, marking the official launch of the "Guangdong-Hong Kong-Macau Greater Bay Area Brain Science and Central Nervous System Disease AI Innovation Alliance" [1] Group 2 - Heartway Medical-B's latest price is 54.000, with a total market capitalization of 2.069 billion and a year-to-date increase of 146.01% [2] - Brain Dynamics-B's latest price is 6.790, with a total market capitalization of 8.598 billion and a year-to-date increase of 110.87% [2] - Nanjing Panda Electronics' latest price is 4.650, with a total market capitalization of 4.249 billion and a year-to-date increase of 35.57% [2] - Brainhole Technology's latest price is 0.230, with a total market capitalization of 0.0184 billion and a year-to-date increase of 1.77% [2] - Microneuroscience's latest price is 11.000, with a total market capitalization of 6.336 billion and a year-to-date increase of 30.18% [2]

心玮医疗-B(6609.HK)大涨超12%，最高触及54.05港元。 消息面上，光大证券发表研报指，脑机接口作为生命科学与信息技术融合的前沿领域，现在正处于政策 支持加码、技术快速迭代、商业化加速落地的关键阶段，全球近百亿美元蓝海市场加速开启。该行指 出，侵入式、半侵入式与介入式技术在信号质量、控制精度上具备不可替代优势，是复杂应用场景的核 心解决方案，国内企业在柔性电极、汉语实时解码等领域实现技术突破，国产化替代加速，长期成长潜 力显著，建议关注心玮医疗等。 在政策端，12月18日，国家药监局在北京召开脑机接口医疗器械工作推进会。会议要求，要坚持安全有 效为首要前提，创新审评监管方法，构建标准体系，加强技术指导服务；要加强跨部门合作，联手产学 研医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责任，以问题为导向，提升产 品可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床、惠及患者。(格隆汇) ...

Summary of New Wei Medical Conference Call Company Overview - **Company**: New Wei Medical - **Industry**: Medical Devices, specifically focusing on brain-computer interface (BCI) technology and drug balloon stents Key Points and Arguments Brain-Computer Interface (BCI) Development - New Wei Medical plans to obtain the inspection report for its BCI product in Q1 2026 and will communicate clinical plans with hospitals in Q2 2026, aiming for the first patient to undergo implantation in the same year, targeting conditions like ALS and stroke-related limb dysfunction [2][3] - The company is facing regulatory challenges with its BCI product and is engaging with review agencies through a project to ensure smooth approval processes, referencing similar companies' experiences [2][6] - Stroke is the leading cause of disability and death in China, with approximately 3 million new cases annually and over 20 million existing patients, many of whom suffer from limb dysfunction post-treatment [9] Clinical Development Plans - New Wei Medical aims to finalize clinical plans with top hospitals by June 2026, with ethical approvals expected within three months and patient recruitment starting in Q4 2026 [5] - The clinical trial will involve 20 to 30 patients, with follow-up periods of 6 to 12 months to assess safety and efficacy [5][6] Financial Projections - The company expects a revenue growth of 30% to 35% in 2026, projecting total revenue between 520 million to 530 million yuan [4][21] - Mid-term goals include achieving over 1 billion yuan in revenue by 2028, with an operating profit margin exceeding 20% [4][22] Product Pricing and Market Strategy - The invasive implantation cost is approximately 6,000 yuan, with the final product price expected to be between 200,000 to 300,000 yuan, referencing DBS products for pricing strategy [10][17] - New Wei Medical plans to gradually reduce prices to increase market penetration, targeting a significant population of stroke and ALS patients [17] Regulatory and Technical Challenges - The BCI product faces high regulatory scrutiny due to its innovative nature, with ongoing discussions with regulatory bodies to ensure compliance [6][10] - The company has validated the safety and signal transmission stability of its technology through animal trials, with plans for human trials in 2026 [3] Research and Development - The BCI product consists of a domestically produced electrode stent and an internationally sourced signal processing unit, with ongoing collaborations with domestic chip design companies [11][12] - The company has invested several million yuan annually since 2021 into the BCI project, with a dedicated team of over 10 people established for its development [18] Future Investment Directions - New Wei Medical will continue to focus on the neuro-intervention sector, exploring partnerships and acquisitions to enhance its product offerings [19][20] - The company plans to apply for A-share listing in 2026 to improve liquidity and support growth [25] Competitive Positioning - New Wei Medical's drug balloon stent is expected to receive approval by Q4 2026, positioning it as a significant growth driver [24] - The company aims to maintain a competitive edge in the BCI market by leveraging government support and focusing on product innovation [24] Additional Important Information - The company anticipates that the new BCI business will gradually contribute to revenue, although the exact impact will depend on market promotion efforts [21] - New Wei Medical's operational strategy includes maintaining stable management and R&D expenses to support growth [23]

Group 1 - The "Annual Outstanding Healthcare Enterprises" award recognizes companies in the Chinese healthcare industry that excel in innovation, technological leadership, market influence, social value, and sustainable development [4] - The award winners include Alibaba Health (00241.HK), Anxuyuan, Baize Medical (02609.HK), Gushengtang (02273.HK), Haijia Medical (06078.HK), Jinhua Medical Group (01110.HK), Kangchen Pharmaceutical (01681.HK), Ping An Good Doctor (01833.HK), Weitai Medical-B (02235.HK), and Xinwei Medical-B (06609.HK) [1] - The selection process involved quantitative data analysis and an expert review panel to determine the final results [4] Group 2 - The "Jin Ge Award" aims to create a reference for the investment community by highlighting the most valuable listed companies and unicorns in China [4] - The evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4]

Core Viewpoint - The demand for cerebrovascular interventional devices in China is increasing due to the rising incidence of cerebrovascular diseases, which are among the top three causes of death in the country, with stroke being the leading cause [1][10]. Industry Definition and Classification - Cerebrovascular diseases are conditions affecting blood vessels in the brain, primarily including ischemic and hemorrhagic strokes. Cerebrovascular interventional surgery involves minimally invasive techniques for diagnosing and treating these conditions [2]. - Cerebrovascular interventional devices include medical consumables required for these surgeries, such as embolization coils, thrombectomy stents, and aspiration catheters [2]. Industry Characteristics - The cerebrovascular interventional device industry is characterized by high technical barriers, continuous technological innovation, and favorable industry policies [4]. Current Industry Status Global Market - The global market for cerebrovascular interventional devices is projected to reach USD 3.292 billion in 2024, with North America accounting for 43.04% of the market, Europe 26.56%, and Asia-Pacific 25.27%. The market is expected to grow to USD 3.974 billion by 2025 [7]. Chinese Market - In China, the market for cerebrovascular interventional devices is expected to reach CNY 3.504 billion in 2024, with specific segments such as intracranial thrombectomy stents at CNY 1.584 billion and aspiration catheters at CNY 0.272 billion. By 2025, the market is projected to grow to CNY 4.879 billion [10][13]. Industry Supply Chain - The upstream of the cerebrovascular interventional device industry consists of raw material suppliers, including tubing and alloy materials. The midstream includes manufacturers like Medtronic and Johnson & Johnson, while the downstream consists of distribution channels and end customers, primarily medical institutions [15].

《变更股份激励的股份来源(注销现有股份奖励及授出新股份奖励)》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 截至2025年12月16日收盘，心玮医疗-B（06609）报收于49.66元，较前一交易日下跌1.66%。该股当日 开盘价为52.45元，盘中最高触及52.6元，最低下探至48.74元，全天成交额为296.11万元。近52周内，该 股最高报71.25元，最低为20.1元。 近日，上海心玮医疗科技股份有限公司发布公告称，董事会已决议变更股份激励计划的股份来源。公司 将注销根据2021年H股激励计划授出的430,500股奖励股份，该等股份原授予集团四名管理层及高级管理 层雇员。同日，公司依据2025年5月26日采纳的2025年H股激励计划，向相同承授人授出合计430,500股 H股作为新股份奖励，发行价为零。此次授出的新奖励股份占公司已发行H股总数约1.39%，占已发行 股本总额约1.12%。新奖励将于2027年6月30日归属，须满足个人表现目标（年度评估达"B"级以上）及 董事会厘定的财务、运营或市值目标。若出 ...

董事会宣布，于2025年12月15日，待达成承授人同意注销先前授出奖励后，公司将根据公司于2025年5 月26日采纳的2025年H股激励计划向承授人授出430,500份股份奖励(「2025年12月授出」)，以取代先前 授出奖励。 格隆汇12月15日丨心玮医疗-B(06609.HK)宣布，于2025年12月15日，其已决议注销根据2021年H股激励 计划向集团若干管理人员授出的430,500股奖励股份(「先前授出奖励」)。董事会认为，注销先前授出奖 励及重新授出新股份奖励将激励承授人为集团的成功作出最大努力并奖励其持续努力，以及提高效率并 降低公司管理其现有激励计划的成本。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 變更股份激勵的股份來源 （註銷現有股份獎勵及授出新股份獎勵） 本公告由上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」） 第17.06A條刊發。 變更股份激勵的股份來源 茲提述本公司於2021年11月1日採納的2021年H股激勵計劃（隨後經修訂「2021年 H股激勵計劃」）。 本公司董事（「董事」）會（「董事會」）欣然宣佈，其建議通過實施以下步驟變更 其股份激勵計劃的股份來源。董事會認為，註銷先前授出獎勵（定義見下文）及 重新授出新股份獎 ...